Galectin‑9 ameliorates fulminant liver injury

Area of Science:

• Hepatology
• Immunology
• Molecular Biology

Background:

• Fulminant hepatitis is a severe liver disease characterized by hepatocyte necrosis.
• Galectin-9 (Gal-9) is a potential therapeutic agent modulating the host immune system.
• Concanavalin A (ConA) injection in mice mimics human immune-mediated hepatitis.

Purpose of the Study:

• To investigate the therapeutic effects of Gal-9 on ConA-induced fulminant hepatitis in vivo.
• To identify microRNAs (miRNAs) associated with Gal-9's immune-modulating effects in fulminant hepatitis.

Main Methods:

• Utilized a ConA-induced mouse hepatitis model.
• Assessed overall survival rates, liver enzymes, and histopathology.
• Performed TUNEL assay, immunohistochemistry, and miRNA expression profiling.

Main Results:

• Gal-9 treatment significantly increased survival rates in ConA-injected mice.
• Gal-9 attenuated hepatocellular damage, reduced neutrophil infiltration, and inhibited macrophage accumulation and hepatocyte apoptosis.
• Identified specific miRNAs induced by Gal-9 potentially mediating its protective effects.

Conclusions:

• Gal-9 demonstrates significant therapeutic potential for treating fulminant hepatitis.
• Gal-9's anti-apoptotic, anti-inflammatory, and pro-proliferative effects on hepatocytes contribute to its efficacy.
• Gal-9 represents a promising candidate therapeutic target for fulminant hepatitis.